Search Result

Results for "

anti-CD40

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Checkpoint Kinase (Chk) (2) CTLA-4 (2) Cytochrome P450 (1) Drug-Linker Conjugates for ADC (4) Glucocorticoid Receptor (3) JAK (1) Microtubule/Tubulin (2) PD-1/PD-L1 (2) Salt-inducible Kinase (SIK) (1) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (12)
By Research Areas:	Cancer (10) Infection (1) Inflammation/Immunology (9)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990111

*BMS-986325 (anti-CD40)*	TNF Receptor	Inflammation/Immunology
BMS-986325 (anti-CD40) is a CD40 inhibitor, and can be used for primary Sj gren's syndrome research .

HY-49382

Fluocinolone acetonide 3-benzylaniline	Target Protein Ligand-Linker Conjugates	Others
Fluocinolone acetonide 3-benzylaniline (Precursor Example 1) is a glucocorticoid receptor agonist-linker conjugate, which can be used for the synthesis of anti-CD40 antibody-drug conjugates (ADCs) .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, *anti-CD40* monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P99663

Inezetamab	TNF Receptor	Cancer
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .

HY-152121

Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal	Glucocorticoid Receptor Drug-Linker Conjugates for ADC	Infection Inflammation/Immunology
Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal is a glucocorticoid receptor agonist. Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used in anti-CD40 antibody agent conjugate (ADC). Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal can be used for the research of inflammation and immune regulation .

HY-P990726

Abiprubart	TNF Receptor	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-153345

Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br	Drug-Linker Conjugates for ADC Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br is an Drug-linker conjugates for ADC that can be used as a reaction reagent for the synthesis of anti-CD40 antibody agent conjugates (ADCs) .

HY-400878

Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal	Glucocorticoid Receptor Drug-Linker Conjugates for ADC	Cancer
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal, a glucocorticoid receptor agonist, is a drug-linker conjugate for ADC. Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal can be used to synthesize the anti-CD40 antibody agent conjugates (WO2019106608A1; example 9) .

HY-171590

SIK2-IN-3	Salt-inducible Kinase (SIK)	Inflammation/Immunology
SIK2-IN-3 is an orally active SIK1/2 selective inhibitor (IC₅₀: 0.128/0.084 μM). SIK2-IN-3 inhibits CRTC3 phosphorylation and myeloid cell pro-inflammatory cytokine production. SIK2-IN-3 ameliorates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model .

HY-148459

ATAC21	Drug-Linker Conjugates for ADC	Cancer
ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate .

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P991513

BI-655064	TNF Receptor	Inflammation/Immunology
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .

HY-P991525

2141-V11	TNF Receptor	Cancer
2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P991555

XmAb5485	TNF Receptor Apoptosis	Cancer
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .

HY-19916A

Lisavanbulin dihydrochloride BAL-101553 dihydrochloride	Microtubule/Tubulin TNF Receptor CTLA-4 PD-1/PD-L1 Checkpoint Kinase (Chk)	Cancer
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .

HY-19916

Lisavanbulin BAL-101553	Microtubule/Tubulin Checkpoint Kinase (Chk) TNF Receptor PD-1/PD-L1 CTLA-4	Cancer
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .

HY-P99315

Ruplizumab BG 9588; anti-Human CD40L Recombinant antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to *CD40L, Ruplizumab blocks its interaction with the CD40* receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-131968

BMS-986202	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

Cat. No.	Product Name	Target	Research Area

HY-P990860

Anti-CD40 Antibody (G28.5)	Inhibitory Antibodies	Others
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1, κ chimeric antibody, targeting to human *CD40. The recommend isotype control of Anti-CD40* Antibody (G28.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P990111

*BMS-986325 (anti-CD40)*	TNF Receptor	Inflammation/Immunology
BMS-986325 (anti-CD40) is a CD40 inhibitor, and can be used for primary Sj gren's syndrome research .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, *anti-CD40* monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P99663

Inezetamab	TNF Receptor	Cancer
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .

HY-P990726

Abiprubart	TNF Receptor	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P991513

BI-655064	TNF Receptor	Inflammation/Immunology
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .

HY-P991525

2141-V11	TNF Receptor	Cancer
2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer .

HY-P991555

XmAb5485	TNF Receptor Apoptosis	Cancer
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .

HY-P99640

Giloralimab ABBV-927	Inhibitory Antibodies	Cancer
Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer .

HY-P99315

Ruplizumab BG 9588; anti-Human CD40L Recombinant antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to *CD40L, Ruplizumab blocks its interaction with the CD40* receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Chemical Structure

HY-131968

BMS-986202
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.